- Report
- July 2024
- 350 Pages
Global
From €1689EUR$1,859USD£1,434GBP
€2413EUR$2,655USD£2,049GBP
- Report
- March 2023
- 280 Pages
Global
From €2348EUR$2,583USD£1,994GBP
€3354EUR$3,690USD£2,848GBP
- Report
- September 2022
- 341 Pages
Global
From €2443EUR$2,688USD£2,075GBP
€3490EUR$3,840USD£2,964GBP
- Report
- October 2021
- 183 Pages
Global
From €2362EUR$2,598USD£2,006GBP
€3374EUR$3,712USD£2,865GBP
- Report
- March 2021
- 268 Pages
Global
From €2362EUR$2,598USD£2,006GBP
€3374EUR$3,712USD£2,865GBP
- Book
- April 2022
- 288 Pages
- Book
- December 2011
- 368 Pages
€2785EUR$3,282USD£2,448GBP
- Book
- February 2024
North America

Asthma is a chronic respiratory condition that affects the airways of the lungs. It is characterized by inflammation, narrowing of the airways, and increased mucus production, which can lead to difficulty breathing, wheezing, and coughing. Asthma is one of the most common chronic diseases in the world, and is a major cause of morbidity and mortality.
The asthma market within the context of pulmonary medicine is a rapidly growing sector, with a wide range of products and services available to treat and manage the condition. These include inhalers, nebulizers, and other devices to deliver medication, as well as monitoring and diagnostic tools. In addition, there are a variety of medications available to treat asthma, including corticosteroids, bronchodilators, and leukotriene modifiers.
Some of the major companies in the asthma market include GlaxoSmithKline, Merck, Novartis, Boehringer Ingelheim, and AstraZeneca. Show Less Read more